Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 16/20 | 0.62 |
| ▸ | PGR | P06401 | 5/20 | 0.57 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.55 |
| ▸ | SMO | Q99835 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2499290 | 0.87 | NR3C1 (0.56) | NR3C1PGRCYP11B2SMO | |
| SCHEMBL5135413 | 0.86 | CYP11B2 (0.71) | NR3C1PGRCYP11B2 | |
| SCHEMBL836802 | 0.84 | NPC1 (0.48) | NR3C1PGRCYP11B2SMO | |
| SCHEMBL2499293 | 0.82 | NR3C1 (0.51) | NR3C1PGRCYP11B2SMO | |
| SCHEMBL22225746 | 0.82 | NR3C1 (0.74) | NR3C1PGRCYP11B2 | |
| SCHEMBL836103 | 0.82 | CYP11B2 (0.47) | NR3C1PGRCYP11B2SMO | |
| SCHEMBL413100 | 0.81 | NR3C1 (0.62) | NR3C1PGRCYP11B2SMO | |
| SCHEMBL3011613 | 0.81 | NR3C1 (0.62) | NR3C1PGRCYP11B2SMO | |
| SCHEMBL29573526 | 0.81 | NR3C1 (0.62) | NR3C1PGRCYP11B2SMO | |
| SCHEMBL836018 | 0.81 | NR3C1 (0.78) | NR3C1PGRCYP11B2SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522586-B2 | Substituted pyrrolidine amines and amides VI | GRUENENTHAL GMBH (DE) | 2026-01-13 | — | — | US | disclosed |
| EP-4178954-B1 | SUBSTITUTED PYRROLIDINE AMINES AND AMIDES AS MEDIATOR OF THE GLUCOCORTOID RECEPTOR | GRUENENTHAL GMBH (DE) | 2025-11-19 | — | — | EP | disclosed |
| US-12358907-B2 | Substituted pyrrolidine amides III | Grünenthal GmbH (DE) | 2025-07-15 | — | — | US | disclosed |
| US-12344605-B2 | Substituted pyrrolidine amides II | GRUENENTHAL GMBH (DE) | 2025-07-01 | — | — | US | disclosed |
| US-12331034-B2 | Substituted pyrrolidine amides V | GRUENENTHAL GMBH (DE) | 2025-06-17 | — | — | US | disclosed |
| CN-113382990-B | Substituted pyrrolidinamide III | 格吕伦塔尔有限公司 | 2024-11-19 | — | — | CN | disclosed |
| US-20230265078-A1 | SUBSTITUTED PYRROLIDINE AMINES AND AMIDES VI | GRUENENTHAL GMBH (DE) | 2023-08-24 | — | — | US | disclosed |
| US-20230265078-A1 | SUBSTITUTED PYRROLIDINE AMINES AND AMIDES VI | GRUENENTHAL GMBH (DE) | 2023-08-24 | — | — | US | disclosed |
| US-20230265078-A1 | SUBSTITUTED PYRROLIDINE AMINES AND AMIDES VI | GRUENENTHAL GMBH (DE) | 2023-08-24 | — | — | US | disclosed |
| EP-4178954-A1 | SUBSTITUTED PYRROLIDINE AMINES AND AMIDES AS MEDIATOR OF THE GLUCOCORTOID RECEPTOR | Grünenthal GmbH (DE) | 2023-05-17 | — | — | EP | disclosed |
| EP-2097384-A1 | INDOZALYL SULPHONAMIDE DERIVATIVES USEFUL AS GLUCOCORTICOID MODULATORS | AstraZeneca AB (SE) | 2009-09-09 | — | — | EP | disclosed |
| EP-2094692-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1 AND/OR NF-KAPPAB ACTIVITY AND USE THEREOF | Brystol-Myers Squibb Company (US) | 2009-09-02 | — | — | EP | disclosed |
| US-20080214641-A1 | Chemical compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | US | disclosed |
| US-20080207721-A1 | Chemical compounds | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-08-28 | — | — | US | disclosed |
| WO-2008076048-A1 | INDAZOLYL ESTER AND AMIDE DERIVATIVES FOR THE TREATMENT OF GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008063116-A1 | INDOZALYL SULPHONAMIDE DERIVATIVES USEFUL AS GLUCOCORTICOID MODULATORS | ASTRAZENECA AB (SE) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008057856-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1 AND/OR NF-KAPPAB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057856-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1 AND/OR NF-KAPPAB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057857-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057857-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358907-B2 | Substituted pyrrolidine amides III | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 35/4885CYP11B2 15/4885 |
| US-20080214641-A1 | Chemical compounds 572 | ABCG2, ABCB1, CYP11B2 | NR3C1 2841/4885PGR 1005/4885CYP11B2 3/4885 |
| US-12331034-B2 | Substituted pyrrolidine amides V | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 32/4885CYP11B2 21/4885 |
| US-20080207721-A1 | Chemical compounds | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 263/4885CYP11B2 5/4885 |
| US-12344605-B2 | Substituted pyrrolidine amides II | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 40/4885CYP11B2 12/4885 |
| US-20230265078-A1 | SUBSTITUTED PYRROLIDINE AMINES AND AMIDES VI | NR3C1, MC2R, NR3C2 | NR3C1 1/4885PGR 20/4885CYP11B2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.